CNCR vs. SCHD

Last updated Jun 3, 2026

CNCR (Loncar Cancer Immunotherapy ETF) and SCHD (Schwab U.S. Dividend Equity ETF) are both exchange-traded funds - CNCR is a Health & Biotech Equities fund tracking the Loncar Cancer Immunotherapy Index, while SCHD is a Dividend fund tracking the Dow Jones U.S. Dividend 100 Index. Both are passively managed. CNCR charges 0.79%/yr vs 0.06%/yr for SCHD.

Performance

CNCR vs. SCHD - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Loncar Cancer Immunotherapy ETF (CNCR) and Schwab U.S. Dividend Equity ETF (SCHD). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

CNCR

• 1D: 0.00%
• 1M: 0.00%
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

SCHD

• 1D: 0.59%
• 1M: 1.60%
• YTD: 19.01%
• 6M: 20.36%
• 1Y: 28.08%
• 3Y*: 15.09%
• 5Y*: 8.49%
• 10Y*: 12.77%

*Multi-year figures are annualized to reflect compound growth (CAGR)

CNCR vs. SCHD - Yearly Performance Comparison

	2026 (YTD)
CNCR Loncar Cancer Immunotherapy ETF	0.00%
SCHD Schwab U.S. Dividend Equity ETF	3.73%

CNCR vs. SCHD - Sectors Allocation Comparison

Sectors	CNCR	SCHD
Healthcare	96.6%	18.8%
Financial Services	3.3%	9.3%
Basic Materials	-	1.2%
Communication Services	-	6.3%
Consumer Cyclical	-	6.3%
Consumer Defensive	-	19.2%
Energy	-	16.2%
Industrials	-	7.5%
Real Estate	-	-
Technology	-	16.4%
Utilities	-	0.0%

Return for Risk

CNCR vs. SCHD — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SCHD

SCHD Risk / Return Rank: 82
SCHD Sharpe Ratio Rank: 78
SCHD Sortino Ratio Rank: 87
SCHD Omega Ratio Rank: 76
SCHD Calmar Ratio Rank: 92
SCHD Martin Ratio Rank: 77

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CNCR vs. SCHD - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Loncar Cancer Immunotherapy ETF (CNCR) and Schwab U.S. Dividend Equity ETF (SCHD). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	CNCR	SCHD	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	—	2.57	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	0.59	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.77	—
Sharpe Ratio (All Time) Calculated using the full available price history	—	0.86	—

Drawdowns

CNCR vs. SCHD - Drawdown Comparison

The maximum CNCR drawdown since its inception was 0.00%, smaller than the maximum SCHD drawdown of -33.37%. Use the drawdown chart below to compare losses from any high point for CNCR and SCHD.

Drawdown Indicators

	CNCR	SCHD	Difference
Max Drawdown Largest peak-to-trough decline	0.00%	-33.37%	+33.37%
Max Drawdown (1Y) Largest decline over 1 year	—	-4.61%	—
Max Drawdown (3Y) Largest decline over 3 years	—	-16.13%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-16.85%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-33.37%	—
Current Drawdown Current decline from peak	0.00%	-1.40%	+1.40%
Average Drawdown Average peak-to-trough decline	0.00%	-3.32%	+3.32%
Ulcer Index Depth and duration of drawdowns from previous peaks	—	1.87%	—

Volatility

Volatility by Period

	CNCR	SCHD	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	2.92%	—
Volatility (6M) Calculated over the trailing 6-month period	—	7.66%	—
Volatility (1Y) Calculated over the trailing 1-year period	0.00%	10.96%	-10.96%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	0.00%	14.38%	-14.38%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	0.00%	16.72%	-16.72%

CNCR vs. SCHD - Expense Ratio Comparison

CNCR has a 0.79% expense ratio, which is higher than SCHD's 0.06% expense ratio.

Dividends

CNCR vs. SCHD - Dividend Comparison

CNCR has not paid dividends to shareholders, while SCHD's dividend yield for the trailing twelve months is around 3.26%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
CNCR Loncar Cancer Immunotherapy ETF	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SCHD Schwab U.S. Dividend Equity ETF	3.26%	3.82%	3.64%	3.49%	3.39%	2.78%	3.16%	2.98%	3.06%	2.63%	2.89%	2.97%

Frequently Asked Questions

Which ETF is better, CNCR or SCHD?

On fees, SCHD is cheaper at 0.06% per year. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF is cheaper, CNCR or SCHD?

SCHD is cheaper with a 0.06% expense ratio, compared with 0.79% for CNCR.

Which ETF pays a higher dividend yield, CNCR or SCHD?

SCHD has the higher dividend yield at 3.26%, compared with 0.00% for CNCR.

What is the main difference between CNCR and SCHD?

CNCR is categorized as Health & Biotech Equities, while SCHD is Dividend. CNCR tracks Loncar Cancer Immunotherapy Index, while SCHD tracks Dow Jones U.S. Dividend 100 Index. They also come from different issuers: Exchange Traded Concepts and Charles Schwab. Their fees differ too: 0.79% for CNCR and 0.06% for SCHD.